Mission Statement

Retrotope is developing a new class of drugs designed to combat the disease and cellular degeneration that results from lipid peroxidation (LPO). By leveraging our unique insight into LPO and our proprietary technology platform, we have created a pipeline of first-in-class therapeutic candidates for the treatment of a range of devastating degenerative diseases.

Our lead drug candidate, RT001, is currently in late-stage clinical trials for the treatment of several orphan neurodegenerative diseases with few or no treatment options. This include amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), Friedreich’s ataxia (FA) and infantile neuroaxonal dystrophy (INAD).

On the web